Clinical Trials for Liver Cancer

An International Multicenter Randomized Controlled Trial to Compare Combined Portal and Hepatic Vein Embolization (PVE/HVE) with PVE Alone in Patients with Colorectal Liver Cancer Metastases (CRLM) and a Small Future Liver Remnant (FLR)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with colorectal liver metastases and insufficient future liver remnant (<30%, or <40% post-chemotherapy), including select patients with intact primaries and resectable/ablatable extrahepatic disease, are randomized to standard portal vein embolization versus combined portal plus hepatic vein embolization to induce FLR hypertrophy prior to hepatectomy. The trial compares rates and speed of achieving resectable FLR and downstream survival and perioperative outcomes.

ClinicalTrials.gov ID: NCT05428735

An Open-Label, Dose Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults With Advanced Hepatocellular Carcinoma (HCC) (ARYA-3)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable/metastatic, GPC3-positive HCC after ≥2 prior systemic therapies receive lymphodepleting cyclophosphamide/fludarabine followed by ECT204, an autologous ARTEMIS AbTCR T-cell therapy targeting glypican-3 designed to retain cytotoxicity with reduced cytokine release versus CAR T cells. Phase 2 includes cohorts of ECT204 at the RP2D with or without regorafenib pre-treatment to assess impact on safety and efficacy.

ClinicalTrials.gov ID: NCT04864054

A Phase II Randomized Study of Atezolizumab Plus Multi-Kinase Inhibitor Versus Multi-Kinase Inhibitor Alone in Subjects With Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab Plus Bevacizumab

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable/advanced HCC (ECOG 0–1, Child-Pugh A) who progressed on first-line atezolizumab plus bevacizumab are randomized to cabozantinib or lenvatinib with or without atezolizumab. Atezolizumab is an anti–PD-L1 antibody restoring T-cell activity; cabozantinib and lenvatinib are VEGFR-targeting multi-kinase inhibitors.

ClinicalTrials.gov ID: NCT05168163

Phase 2, Single Arm Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with HLA-A*02:01–positive metastatic uveal melanoma predominantly confined to the liver receive Y-90 transarterial radioembolization followed by weekly tebentafusp. Tebentafusp is a bispecific gp100–HLA-A*02:01–targeted TCR/anti-CD3 ImmTAC that redirects T cells to melanoma cells; key exclusions include large (>8 cm) dominant liver lesions, significant hepatic dysfunction, vascular shunting precluding TARE, and active CNS metastases requiring steroids.

ClinicalTrials.gov ID: NCT06627244

UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2/3 Neuroendocrine Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable, liver-dominant, well-differentiated grade 2 or 3 neuroendocrine tumors (ECOG 0–2, measurable liver lesion, adequate organ function, patent portal vein) receive capecitabine-temozolomide (thymidylate synthase inhibition plus DNA alkylation) combined with staged intrahepatic Y-90 radioembolization. Prior systemic therapy is allowed with washout; prior liver-directed embolization or radioembolization is excluded.

ClinicalTrials.gov ID: NCT04339036

A Phase II Clinical Trial of Anti-PD-1 mAb Therapy Alone or With Metabolic Modulators to Reverse Tumor Hypoxia and Immune Dysfunction in Solid Tumor Malignancies

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced solid tumors eligible for standard anti–PD-1 monotherapy (e.g., melanoma, RCC, NSCLC, HCC Child-Pugh A, MSI-H tumors, urothelial, GEJ/gastric adenocarcinoma, HNSCC) are randomized to nivolumab or pembrolizumab alone versus combined with metformin (mitochondrial complex I inhibitor/AMPK activator) or rosiglitazone (PPAR-γ agonist) to reduce tumor hypoxia and improve immune function. Requires measurable disease, ECOG 0–2, and mandatory pre/post-treatment biopsies; excludes prior PD-1/PD-L1 therapy and significant cardiopulmonary/autoimmune contraindications.

ClinicalTrials.gov ID: NCT04114136

Phase IIA Single-Arm Study of Treatment of Patients With Advanced Liver Cancer With a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD-1 Monoclonal Antibody

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced hepatocellular carcinoma (Child-Pugh A–B7) or metastatic gastric/gastroesophageal cancer with ≥1 liver lesion, who have progressed on prior immune checkpoint inhibitor therapy (or chemo plus ICI for gastric/GE), receive nivolumab (PD‑1 inhibitor) plus transarterial tirapazamine embolization (TATE), a hypoxia-activated prodrug delivered with embolization to intensify local tumor kill and potentially augment systemic immunity. Requires ECOG 0–2 and adequate organ function; excludes recent major GI bleeding and significant autoimmune disease.

ClinicalTrials.gov ID: NCT03259867

vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with unresectable, locally advanced or metastatic HCC (or mixed HCC-CCA), ECOG 0–1 and Child-Pugh A–B7, receive a single-fraction vGRID SBRT dose-escalation (27–47 Gy; de-escalation to 40 Gy in 5 fractions if needed) targeting part of the tumor with high dose while respecting liver/GI constraints. Standard atezolizumab (PD-L1 inhibitor) starts 12–16 days post-SBRT with bevacizumab held for cycle 1 to reduce GI risk.

ClinicalTrials.gov ID: NCT05727787

The Role of Checkpoint Inhibition in Relapsed/Refractory Pediatric Hepatocellular Carcinoma: Clinical Efficacy and Biologic Correlates - A Phase II Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Single-arm study of pembrolizumab (anti–PD-1) given IV q3 weeks in children, adolescents, and young adults (<30 years) with relapsed/refractory hepatocellular carcinoma or hepatocellular neoplasm NOS, requiring measurable disease and adequate performance/organ function. Excludes prior checkpoint inhibitor therapy, active autoimmune disease, chronic immunosuppression, and prior solid organ transplant; assesses responses by irRECIST with planned tumor/immune biomarker correlatives.

ClinicalTrials.gov ID: NCT04134559

Phase II Trial of Palliative Hypofractionated Radiotherapy Followed by Durvalumab (MEDI4736) With/Without Tremelimumab for Advanced Hepatocellular Carcinoma After Progression on Prior PD-1 Inhibition

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced HCC (ECOG 0–1, Child-Pugh A–B8) requiring palliative RT who have progressed on prior anti–PD-1 therapy (no prior PD-L1/CTLA-4) receive short-course hypofractionated RT followed by durvalumab (anti–PD-L1) with or without tremelimumab (anti–CTLA-4). Excludes active autoimmune disease or significant unresolved irAEs; evaluates responses in non-irradiated lesions with optional tremelimumab re-dose at progression after initial benefit.

ClinicalTrials.gov ID: NCT04430452